CAS: 99807-54-2; Methyl 2-(4-(Bromomethyl)Phenyl)Propanoate
该化合物是一种化学化合物,被确认为与药物的抗炎药物(非非类物质抗炎药物)有关的一种杂质.虽然有关Loxoproferen Inferity 18的具体细节可能没有广泛的文件记载,但在合成或降解活性药物成分期间通常会出现药品杂质.这种杂质可能影响药物的功效,安全和稳定性.一般而言,杂质的特征是其分子结构,其中可能包括能影响其反应和相互作用的功能组别.通过制药生产中的质量管制措施监测Loxoproprofen Inferive 18等杂质的存在,以确保符合监管标准.了解这种杂质的特点对于评估其对药物配方和病人安全的潜在影响至关重要.可能需要进一步研究,以阐明其具体的化学特性,生物活动和毒理学特征.
- 英文名称Methyl 2-(4-(Bromomethyl)Phenyl)Propanoate
- 中文名称洛索洛芬杂质18
- IUPAC名称Methyl 2-(4-(bromomethyl)phenyl)propanoate
- 其它别名Loxoprofen Impurity 18; Methyl 2-(4-(Bromomethyl)Phenyl)Propanoate; Benzeneacetic Acid, 4-(Bromomethyl)-α-Methyl-, Methyl Ester; 4-(Bromomethyl)-α-Methyl-Benzeneacetic Acid Methyl Ester; Loxoprofen Impurity/methyl2-(4-Bromomethylphenyl)Propanoate; Methyl 4-(Bromomethyl)-α-Methylbenzeneacetate
- CAS编号99807-54-2
- MFCD编号:MFCD22123847
- EINECS号:988-704-2
- 分子式:C11H13BrO2分子量:257.13
- 产品CID: 2032872
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
MSDS等安全信息
欧盟法规
C&L通报上下游产品
methanol 2-[4-(bromomethyl)phenyl]propanoic acid 1-(1-chloroethyl)-4-methylbenzene (R,S)-2-(4'-methylphenyl) propionic acid Methyl 2-[4-(3-cyano-4-oxothiolan-3-ylmethyl)phenyl]propionate 2-(4-formylphenyl)propionic acid methyl ester loxoprofen methyl ester phenyl>propionatesodium 2-4-(2-ox°Cyclopentyl)methylphenylpropionate合成工艺路线路线简述
📜Methyl 2-(4-Methylphenyl)Propanoate置于n-溴代丁二酰亚胺(Nbs),偶氮二异丁腈体系中,用 四氯化碳 作为反应溶剂,化学反应生成 洛索洛芬杂质18
参考文献:一种洛索洛芬衍生物
标题:一种洛索洛芬衍生物
摘要:本发明提供一种如下式(ⅰ)所示的洛索洛芬衍生物,其中r1为氢原子,取代或未取代的烷基,R2为取代或未取代的烷基,该洛索洛芬衍生物胃肠道副作用低并能够提高生物利用度.
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905121000-正丙醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12129222-B2
优先权日:2016-08-11
标题:Production of bitter principle derivatives
发明人：WYRWA RALF; RODE CLAUDIA; SEEMANN THOMAS; MEINEL LORENZ; RITZER JENNIFER; SCHNABELRAUCH MATTHIAS
权利人:UNIV WUERZBURG J MAXIMILIANS; JULIUS MAXIMILIANS UNIV
摘要:It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1:For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.
